Cargando…

Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer

BACKGROUND: There is increasing evidence of a constitutive activation of Akt in pancreatic ductal adenocarcinoma (PDAC), associated with poor prognosis and chemoresistance. Therefore, we evaluated the expression of phospho-Akt in PDAC tissues and cells, and investigated molecular mechanisms influenc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Massihnia, Daniela, Avan, Amir, Funel, Niccola, Maftouh, Mina, van Krieken, Anne, Granchi, Carlotta, Raktoe, Rajiv, Boggi, Ugo, Aicher, Babette, Minutolo, Filippo, Russo, Antonio, Leon, Leticia G., Peters, Godefridus J., Giovannetti, Elisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5219723/ https://www.ncbi.nlm.nih.gov/pubmed/28061880 http://dx.doi.org/10.1186/s13045-016-0371-1

Ejemplares similares

AKT1 and SELP Polymorphisms Predict the Risk of Developing Cachexia in Pancreatic Cancer Patients
por: Avan, Abolfazl, et al.
Publicado: (2014)

Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia
por: Maftouh, M, et al.
Publicado: (2014)

Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma
por: Maftouh, Mina, et al.
Publicado: (2014)

Role of Akt signaling in resistance to DNA-targeted therapy
por: Avan, Abolfazl, et al.
Publicado: (2016)

Metabolic Effects of New Glucose Transporter (GLUT-1) and Lactate Dehydrogenase-A (LDH-A) Inhibitors against Chemoresistant Malignant Mesothelioma
por: Franczak, Marika A., et al.
Publicado: (2023)

High-Throughput MicroRNA (miRNAs) Arrays Unravel the Prognostic Role of MiR-211 in Pancreatic Cancer
por: Giovannetti, Elisa, et al.
Publicado: (2012)

Profiling of Phospho-AKT, Phospho-mTOR, Phospho-MAPK and EGFR in Non-small Cell Lung Cancer
por: Kitano, Haruhisa, et al.
Publicado: (2014)

5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer
por: Toffalorio, Francesca, et al.
Publicado: (2018)

Lactate dehydrogenase A inhibition by small molecular entities: steps in the right direction
por: El Hassouni, Btissame, et al.
Publicado: (2020)

Correction: Lactate dehydrogenase A inhibition by small molecular entities: steps in the right direction
por: El Hassouni, Btissame, et al.
Publicado: (2021)

Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds
por: Li Petri, Giovanna, et al.
Publicado: (2020)

Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?
por: Peters, Godefridus J., et al.
Publicado: (2019)

3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma
por: Cascioferro, Stella, et al.
Publicado: (2020)

Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells
por: Firuzi, Omidreza, et al.
Publicado: (2019)

Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
por: Ciccolini, Joseph, et al.
Publicado: (2016)

Phospho-Form Specific Substrates of Protein Kinase B (AKT1)
por: McKenna, McShane, et al.
Publicado: (2021)

Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing
por: Rovithi, Maria, et al.
Publicado: (2017)

MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT
por: Yoo, Jung-Yoon, et al.
Publicado: (2018)

Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models
por: Ricci, Claudio, et al.
Publicado: (2014)

Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment
por: Le Large, Tessa Ya Sung, et al.
Publicado: (2019)

hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
por: Meijer, Laura L., et al.
Publicado: (2016)

Wogonin increases gemcitabine sensitivity in pancreatic cancer by inhibiting Akt pathway
por: Zhang, Tianli, et al.
Publicado: (2022)

Upregulated GRB7 promotes proliferation and tumorigenesis of Bladder Cancer via Phospho-AKT Pathway
por: Zheng, Yingchun, et al.
Publicado: (2020)

α-Ketoglutarate Inhibits Thrombosis and Inflammation by Prolyl Hydroxylase-2 Mediated Inactivation of Phospho-Akt
por: Shrimali, Nishith M, et al.
Publicado: (2021)

Increased Phospho‐AKT in Blood Cells from LRRK2 G2019S Mutation Carriers
por: Garrido, Alicia, et al.
Publicado: (2022)

Three-Dimensional Analysis of the Interactions between hLDH5 and Its Inhibitors
por: Poli, Giulio, et al.
Publicado: (2017)

Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy
por: Davies, Janine M, et al.
Publicado: (2011)

miR‐200c and phospho‐AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis
por: Berlanga, Pablo, et al.
Publicado: (2016)

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt
por: Bartholomeusz, Chandra, et al.
Publicado: (2011)

FKBP5 as a Selection Biomarker for Gemcitabine and Akt Inhibitors in Treatment of Pancreatic Cancer
por: Hou, Junmei, et al.
Publicado: (2012)

Elongation Factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility
por: Pecorari, Luisa, et al.
Publicado: (2009)

Phospho-Akt Immunoreactivity in Prostate Cancer: Relationship to Disease Severity and Outcome, Ki67 and Phosphorylated EGFR Expression
por: Hammarsten, Peter, et al.
Publicado: (2012)

Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer
por: Kawaguchi, Hiroshi, et al.
Publicado: (2014)

PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer
por: Li, Wenbin, et al.
Publicado: (2020)

RRP9 promotes gemcitabine resistance in pancreatic cancer via activating AKT signaling pathway
por: Zhang, Zhiqi, et al.
Publicado: (2022)

Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation
por: Pan, Yi-Ru, et al.
Publicado: (2023)

Increased staining for phospho-Akt, p65/RELA and cIAP-2 in pre-neoplastic human bronchial biopsies
por: Tichelaar, Jay W, et al.
Publicado: (2005)

Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway
por: Namba, T, et al.
Publicado: (2015)

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway
por: Massihnia, Daniela, et al.
Publicado: (2016)

Pancreatic Cancer
por: Funel, Niccola, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bvlh190pf8g9027u9rl61a30ls